8 completed. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | Northwestern University | 12 | 2017-09-14 | 2026-06-17 |
| Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer Mirvetuximab Soravtansine - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 96 | 2017-06-05 | 2020-12-02 |
| Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab - Androgen Receptor Positive, Estrogen Receptor Negative | Phase 2 | Completed | City of Hope Medical Center | 18 | 2017-06-01 | 2024-02-20 |
| Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer Anastrozole, Doxorubicin Hydrochloride, Exemestane - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | City of Hope Medical Center | 30 | 2016-03-28 | 2024-03-19 |
| 18F-FSPG PET/CT for Cancer Patients on Therapy 18F-FSPG, 18F-FDG - B-Cell Neoplasm, Estrogen Receptor Negative | Phase 2 | Completed | Andrei Iagaru | 7 | 2015-07-01 | 2019-01-03 |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2013-10-02 | 2019-09-20 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | University of Nebraska | 92 | 2012-12-07 | 2026-06-26 |
| Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer Laboratory Biomarker Analysis, Tivantinib - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2012-03-01 | 2016-03-21 |
Triple Negative Breast Neoplasms (8) · Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Lymphoma, B-Cell (1) · Mesothelioma (1)
Breast Diseases (8) · Neoplasms (8) · Neoplasms by Site (8) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8) · Breast Neoplasms (2) · Adenocarcinoma (1) · Adenoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1)
pembrolizumab (3) · Doxorubicin (2) · (4S)-4-(3-(18F)fluoropropyl)-L-glutamate (1) · 4-(3-fluoropropyl)glutamic acid (1) · ARQ 197 (1) · Anastrozole (1) · Carboplatin (1) · Cyclophosphamide (1) · Fluorodeoxyglucose F18 (1) · GSK2141795 (1) · Letrozole (1) · PF-05280014 (1) · Paclitaxel (1) · Radiation (1) · Radiotherapy (1)
City of Hope Medical Center (2) · National Cancer Institute (NCI) (2) · Andrei Iagaru (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · University of Nebraska (1)
United States (8)
Amulya C Yellala, MD (1) · Andrei M Iagaru, MD (1) · Bhuvaneswari Ramaswamy, MD (1) · James Waisman, MD (1) · Massimo Cristofanilli, MD (1) · Sara Tolaney (1) · Stacy L Moulder (1) · Yuan Yuan (1)
N01CM00070 (1), N01CM00100 (1), P30CA006516 (1), P30CA016058 (1), P30CA036727 (1), P30CA060553 (1), P30CA124435 (1), U01CA062490 (1), UM1CA186712 (1), UM1CA186716 (1)